特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品分析:Menveo

Menveo

発行 Datamonitor Healthcare 商品コード 912148
出版日 ページ情報 英文 12 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.98円で換算しております。
医薬品分析:Menveo Menveo
出版日: 2019年09月03日 ページ情報: 英文 12 Pages
概要

Menveoは、ジフテリア毒素変異体であるCRM-197とリン酸アルミニウムアジュバントを使用する、4価髄膜炎菌複合糖質ワクチンです。

当レポートでは、Menveoについて調査分析し、医薬品の概要、製品プロファイルなどについて、体系的な情報を提供しています。

概要

  • 医薬品の概要
  • 製品プロファイル
  • Menveo:髄膜炎菌ワクチン
目次
Product Code: DMKC0083538

Drug Overview

Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline) is a quadrivalent meningococcal glycoconjugate vaccine that uses CRM-197, a natural mutant of the diphtheria toxin, as well as an aluminum phosphate adjuvant. It is approved for the prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals aged two months to 55 years in both the US and EU.

A large patient population and broad serotype coverage will ensure Menveo continues to compete directly with Menactra (quadrivalent polysaccharide diphtheria toxoid conjugate vaccine; Sanofi), with Menveo's sales gradually increasing at its rival's expense. Menactra is expected to continue to dominate the US market, except in high-risk children aged younger than nine months, for whom Menveo is the only quadrivalent meningococcal conjugate vaccine approved in the country. Menactra covers the same serotypes as Menveo, and due to its earlier launch, Menactra will likely continue to dominate, as the vaccines are interchangeable from a clinical perspective. However, Menveo will capture a greater proportion of EU market share because Menactra is not approved in this region, and Menveo was approved two years before its main rival, Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer). In the long term, GlaxoSmithKline intends to position its pipeline vaccine MenABCW-135Y (pentavalent meningococcal conjugate vaccine) as a successor to Menveo and Bexsero (multicomponent meningococcal serogroup B vaccine), although the combined vaccine's launch is not expected until 2022 in the US and EU.

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
  • Menveo : Meningococcal vaccines

LIST OF TABLES

  • Table 1: Menveo drug profile
  • Table 2: Approval history of Menveo for meningococcal vaccination in the US and five major EU markets
  • Table 3: Late-phase trials of Menveo for meningococcal vaccination
  • Table 4: Menveo for meningococcal disease - SWOT analysis